|
Success
Rates: GIII Series™ and G-media Version 2
| GIII
Series™ - Improved performance (efficacy)
The
efficacy of the GIII Series™ compared to G1.2/G2.2
has been retrospectively studied by the Colorado Centre
for Reproductive Medicine during the period of April
to December 2001. The culture was performed at 37ºC
in 6 % CO2 and 5 % O2. The number of patients, the
average age and the number of embryos transferred
are indicated in Table 1.
The
results (Fig 1) illustrate clearly that the performance
of GIII Series™ is significantly improved in
comparison to the G1.2/G2.2. Blastocyst formation,
implantation and pregnancy rates are increased by
16.1%, 23.9% and 13.3% respectively.
|
Table 1
|
G1.2/G2.2
|
GIII
Series™
|
|
|
No.
patients
|
202
|
96
|
|
|
Age
|
33.2
|
33.3
|
|
|
No.
embryos transferred
|
2.2
|
2.2
|
|
Building
on proven success:
Higher pregnancy rates with G-media versi on
2 from Vitrolif
 In
a prospective randomized study 249 patients undergoing
IVF treatment wererandomly allocated to G1.2/G2.2 or Sydney
IVF media.
For
day 3 transfer G1.2/G2.2 were superior to Sydney IVF media,
whereas both media yielded similar outcomes in a blastocyst
transfer program.
Next
page: Why recombinant human albumin and hyaluronan are
included in the GIII Series™
--------------------------
 Next
page: Why recombinant human albumin and hyaluronan are included
in the GIII Series™
--------------------------
GIII Series , G3 Series
EmbryoGlue®
l GI-Version 3 l G2-Version
3 l GIII l GIII
Product Summary l Scientific
Background
Products l G-Fert
l G-FreezeKit Blast l G-MM
Version 3 l G-Mops l
G-OOCYTE l G-PGD
G-Rinse l G-Sperm
l G-ThawKit Blast l HSA-solution
l References l r-HA
l Success Rates
G-MOPS PLUS l G-SPERM
PLUS l G-FERT PLUS l G-1
v3 PLUS l G-2 v3 PLUS
|
The
GIII Series™ NEW! 
